Kala Pharmaceuticals, a late-stage biotech developing nanoparticle therapies for ocular inflammation, raised $90 million by offering 6 million shares at $15, within the range of $14 to $16.
Kala Pharmaceuticals plans to list on the Nasdaq under the symbol KALA. J.P. Morgan and BofA Merrill Lynch acted as lead managers on the deal.
